Home > Insider Trading > Filing (0001012975-14-000655)

Filing Details

Accession Number:: 0001012975-14-000655
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-10-07 17:34:03
Reporting Period:: 2014-10-03

Filing Date:: 2014-10-07
Accepted Time:: 2014-10-07 17:34:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1293971	Bluebird Bio Inc.	BLUE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1229592	Steven Gillis	C/O Arch Venture Partners 8725 West Higgins Road, Suite 290 Chicago IL 60631		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-10-03	26,635	$35.74	1,186,911	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
Common Stock	Disposition	2014-10-06	24,100	$35.16	1,162,811	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
Common Stock	Disposition	2014-10-07	6,700	$35.15	1,156,111	No	4	S	Indirect	By ARCH Venture Fund VII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.
No	4	S	Indirect	By ARCH Venture Fund VII, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.15, inclusive. The reporting person undertakes to provide to BLUE, any security holder of BLUE, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.75, inclusive
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.67, inclusive.
These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own Fund shares held by ARCH Fund VII. Each Managing Director disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Managing Director is the beneficial owner of such securities for Section 16 or any other purpose.
Steven Gillis owns an interest in ARCH Partners VII but does not have voting or investment control over the shares held by ARCH Fund VII and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that Steven Gillis is the beneficial owner of such securities for Section 16 or any other purpose.